If you are attending ISSCR 2017, you can attend the Asterias workshop, titled «Clinical Development of hESC - derived
Oligodendrocyte Progenitors for the Treatment of Spinal Cord injury» on June 13, 2017 at 10:45 am.
Not exact matches
«There are currently no therapies which successfully reverse the damage seen in the more than 12,000 individuals who suffer a spinal cord injury each year in the United States alone,» says Dr. Richard G. Fessler, professor of neurological surgery at Rush University Medical Center and principal investigator
for the Phase 1 clinical trial involving AST - OPC1 (
oligodendrocyte progenitor cells).
At the International Society
for Stem Cell Research 2017 Annual Meeting (June 14 - 17, 2017; Boston, USA), Asterias Biotherapeutics, Inc (CA, USA) will present new 9 - month efficacy and safety data from their ongoing SCiStar Phase I / IIa trial of human embryonic stem cell - derived
oligodendrocyte progenitor cells.